Sinovac Biotech (SVA) Swings to Q1 Profit

Sinovac Biotech (NASDAQ: SVA) reported Q1 EPS of $0.02, versus ($0.04) reported last year. Revenue for the quarter came in at $11 million, versus $9.2 million reported last year.

Non-GAAP EBITDA was $60 thousand in the first quarter of 2016, compared to a loss of $212 thousand in the prior year period. Non-GAAP net loss from continuing operations in the first quarter of 2016 was $1.4 million, a decrease of 45% compared to $2.6 million in the prior year period.

For earnings history and earnings-related data on Sinovac Biotech (SVA) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Ocean Power Technologies revises fiscal 2026 results after audit
• Target raises full-year sales forecast amid ongoing turnaround drive